These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35712091)

  • 1. Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson's Disease.
    Conti V; Izzo V; Russillo MC; Picillo M; Amboni M; Scaglione CLM; Nicoletti A; Cani I; Cicero CE; De Bellis E; Charlier B; Giudice V; Somma G; Corbi G; Barone P; Filippelli A; Pellecchia MT
    Front Med (Lausanne); 2022; 9():909936. PubMed ID: 35712091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications.
    Adamiak-Giera U; Jawień W; Pierzchlińska A; Białecka M; Kobierski JD; Janus T; Gawrońska-Szklarz B
    Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex Is the Main Determinant of Levodopa Clinical Pharmacokinetics: Evidence from a Large Series of Levodopa Therapeutic Monitoring.
    Contin M; Lopane G; Belotti LMB; Galletti M; Cortelli P; Calandra-Buonaura G
    J Parkinsons Dis; 2022; 12(8):2519-2530. PubMed ID: 36373294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease.
    Safirstein BE; Ellenbogen A; Zhao P; Henney HR; Kegler-Ebo DM; Oh C
    Clin Ther; 2020 Jun; 42(6):1034-1046. PubMed ID: 32482490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection.
    Narożańska E; Białecka M; Adamiak-Giera U; Gawrońska-Szklarz B; Sołtan W; Schinwelski M; Robowski P; Madaliński MH; Sławek J
    Clin Neuropharmacol; 2014; 37(4):96-9. PubMed ID: 24992088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease.
    Nagayama H; Hamamoto M; Ueda M; Nito C; Yamaguchi H; Katayama Y
    Clin Neuropharmacol; 2004; 27(6):270-3. PubMed ID: 15613930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body weight influences pharmacokinetics of levodopa in Parkinson's disease.
    Zappia M; Crescibene L; Arabia G; Nicoletti G; Bagalà A; Bastone L; Caracciolo M; Bonavita S; Di Costanzo A; Scornaienchi M; Gambardella A; Quattrone A
    Clin Neuropharmacol; 2002; 25(2):79-82. PubMed ID: 11981233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill
    LeWitt PA; Giladi N; Navon N
    Parkinsonism Relat Disord; 2019 Aug; 65():131-138. PubMed ID: 31176632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Assessment of Motor Response to a Low Subacute Levodopa Dose in the Differential Diagnosis of Parkinsonisms at Disease Onset: Data from the BoProPark Cohort.
    Contin M; Lopane G; Cortelli P; Sambati L; Mohamed S; Calandra-Buonaura G
    J Parkinsons Dis; 2021; 11(2):811-819. PubMed ID: 33554924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
    Haaxma CA; Horstink MW; Zijlmans JC; Lemmens WA; Bloem BR; Borm GF
    J Parkinsons Dis; 2015; 5(4):847-53. PubMed ID: 26444087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease.
    Rabey JM; Schwartz M; Graff E; Harsat A; Vered Y
    Clin Neuropharmacol; 1991 Dec; 14(6):514-22. PubMed ID: 1773422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Female, aging, difference formulations of DCI, or lower body weight increases AUC
    Nishikawa N; Iwaki H; Shiraishi T; Mukai Y; Takahashi Y; Murata M
    Parkinsonism Relat Disord; 2020 Jul; 76():16-20. PubMed ID: 32554330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study.
    Djaldetti R; Giladi N; Hassin-Baer S; Shabtai H; Melamed E
    Clin Neuropharmacol; 2003; 26(6):322-6. PubMed ID: 14646613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex differences in the pharmacokinetics of levodopa in elderly patients with Parkinson disease.
    Kumagai T; Nagayama H; Ota T; Nishiyama Y; Mishina M; Ueda M
    Clin Neuropharmacol; 2014; 37(6):173-6. PubMed ID: 25384078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk and course of motor complications in a population-based incident Parkinson's disease cohort.
    Bjornestad A; Forsaa EB; Pedersen KF; Tysnes OB; Larsen JP; Alves G
    Parkinsonism Relat Disord; 2016 Jan; 22():48-53. PubMed ID: 26585090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
    Müller T
    Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa in the treatment of Parkinson's disease: an old drug still going strong.
    Poewe W; Antonini A; Zijlmans JC; Burkhard PR; Vingerhoets F
    Clin Interv Aging; 2010 Sep; 5():229-38. PubMed ID: 20852670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease.
    Arabia G; Zappia M; Bosco D; Crescibene L; Bagalà A; Bastone L; Caracciolo M; Scornaienghi M; Quattrone A
    Neurol Sci; 2002 Sep; 23 Suppl 2():S53-4. PubMed ID: 12548340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.
    Kestenbaum M; Fahn S
    Expert Opin Drug Saf; 2015 May; 14(5):761-7. PubMed ID: 25697185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.